Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Recurrence 1Leukemia, Myeloid, Acute 1Leukemia 1

Interventions

Cytarabine 358Cyclophosphamide 241Azacitidine 213fludarabine phosphate 199venetoclax 198fludarabine 196Busulfan 148Decitabine 132Mycophenolic Acid 123Whole-Body Irradiation 122Peripheral Blood Stem Cell Transplantation 118Tacrolimus 115Granulocyte Colony-Stimulating Factor 104Idarubicin 100Filgrastim 100Melphalan 89Cyclosporine 89Methotrexate 83Daunorubicin 76Antilymphocyte Serum 75Etoposide 73Mitoxantrone 67Clofarabine 67Gemtuzumab 59Stem Cell Transplantation 55Thiotepa 51Cladribine 46Injections 45Specimen Handling 44thymoglobulin 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia, Myeloid, Acute × LY2510924 × Clear all
NCT02652871 2019-11-15

LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia

M.D. Anderson Cancer Center

Phase 1 Completed
36 enrolled
Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡